Assenagon Asset Management S.A. Has $649,000 Stock Holdings in Enanta Pharmaceuticals, Inc. $ENTA

Assenagon Asset Management S.A. lessened its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 49.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 54,257 shares of the biotechnology company’s stock after selling 52,123 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Enanta Pharmaceuticals were worth $649,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Farther Finance Advisors LLC grew its position in Enanta Pharmaceuticals by 11,558.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 5,779 shares during the last quarter. MetLife Investment Management LLC bought a new stake in shares of Enanta Pharmaceuticals during the first quarter worth about $72,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Enanta Pharmaceuticals in the second quarter valued at approximately $88,000. Walleye Capital LLC raised its holdings in Enanta Pharmaceuticals by 63.8% in the 1st quarter. Walleye Capital LLC now owns 27,318 shares of the biotechnology company’s stock valued at $151,000 after buying an additional 10,639 shares during the last quarter. Finally, CWM LLC raised its holdings in Enanta Pharmaceuticals by 22.1% in the 2nd quarter. CWM LLC now owns 21,464 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 3,879 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $16.60 on Friday. The business’s fifty day moving average is $12.91 and its 200 day moving average is $9.89. The firm has a market cap of $479.08 million, a price-to-earnings ratio of -4.33 and a beta of 0.96. Enanta Pharmaceuticals, Inc. has a 52-week low of $4.09 and a 52-week high of $17.05.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.26. The business had revenue of $15.13 million for the quarter, compared to analyst estimates of $15.60 million. Enanta Pharmaceuticals had a negative net margin of 125.36% and a negative return on equity of 93.76%. Equities analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on ENTA shares. Jefferies Financial Group raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the stock from $14.00 to $20.00 in a research report on Wednesday, October 1st. Westpark Capital increased their target price on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, September 30th. JPMorgan Chase & Co. began coverage on shares of Enanta Pharmaceuticals in a research note on Friday, November 14th. They issued an “overweight” rating and a $17.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Wednesday, October 8th. Finally, Evercore ISI dropped their price target on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating on the stock in a research report on Monday, September 15th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.33.

Insiders Place Their Bets

In other news, insider Yat Sun Or sold 2,390 shares of the stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $34,009.70. Following the transaction, the insider owned 371,392 shares of the company’s stock, valued at $5,284,908.16. This represents a 0.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jay R. Luly sold 4,743 shares of the firm’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $67,492.89. Following the transaction, the chief executive officer directly owned 858,026 shares in the company, valued at approximately $12,209,709.98. This represents a 0.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 11,961 shares of company stock valued at $170,149 in the last quarter. Corporate insiders own 13.89% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.